[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].

Mutations of BRCA1 and BRCA2 genes account for the majority of hereditary breast and ovarian cancers. So far; risk-reducing salpingo-oophorectomy has been the most effective strategy for gynecological cancer prevention in susceptibility gene mutation carriers. It does not prevent, however from the occurrence of primary peritoneal cancer We present two clinical cases of patients with the BRCA1 gene mutation.

Diagnostic problems concerning epithelioid sarcoma--case analysis.

We discuss here five cases of epithelioid sarcoma (ES) with final diagnosis established after reexamination of initial findings. Problems with differential diagnosis of these neoplasms arise since their microscopic picture may simulate several other pathological conditions such as non-neoplastic granulomatous reactions, squamous cell carcinomas and adenocarcinomas, melanomas and soft tissue sarcomas with epithelioid component. Final ES diagnosis requires presence of cytokeratin, EMA and vimentin in neoplastic cells, as confirmed by immunohistochemical reactions.

BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.

Background: Incidence of primary bilateral breast cancer (BC) is rare and does not exceed 5%. BRCA1/2 mutation carriers diagnosed with breast cancer have a strong life time risk of developing contralateral breast cancer (53% versus 2%).

Patients And Methods: A group of 108 patients with bilateral breast cancer, who reported at our Cancer Centres from 2000 to 2002, were subjected to genetic testing.

[Cytologic prints of primary and metastatic melanomas. Preliminary report].

In 15 cases of melanoma (10 primary tumours and 5 metastatic ones) imprint examination was performed intraoperatively. In one case the material was non-diagnostic. Out of the remaining 14 cases six tumours consisted of epithelioid cells, one--spindle-shaped and seven were of mixed structure.